drugset

drugset / Trial / NCT00904787

Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies

NCT00904787 ↗

Phase 1 Completed 27 enrolled CASI pharmaceuticals, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To define the maximum tolerated dose of oral daily ENMD 2076 in patients with relapsed or refractory hematological malignancies

Timeline

Start: 2009-04
Primary completion: 2010-12
Completion: 2011-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ENMD-2076	Small molecule	—	Oral

Indications